Basal cell carcinoma primary prevention: Difference between revisions
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 12: | Line 12: | ||
{{Diseases of the skin and appendages by morphology}} | {{Diseases of the skin and appendages by morphology}} | ||
{{Tumors of bone, cartilage, skin, connective, and soft tissue}} | {{Tumors of bone, cartilage, skin, connective, and soft tissue}} | ||
<br> | <br> | ||
[[de:Basaliom]] | [[de:Basaliom]] | ||
Revision as of 22:46, 8 August 2012
|
Basal cell carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Basal cell carcinoma primary prevention On the Web |
|
American Roentgen Ray Society Images of Basal cell carcinoma primary prevention |
|
Risk calculators and risk factors for Basal cell carcinoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Prevention and early diagnosis
Basal cell carcinoma is the most common skin cancer. It occurs mainly in fair-skinned patients with a family history of this cancer. Sunlight is a factor in about two-thirds of these cancers, but one-third occur in non-sun-exposed areas. Therefore, doctors recommend sun screens.
The use of a chemotherapeutic agent such as 5-Fluorouracil or Imiquimod, can prevent development of skin cancer. It is usually recommended to individuals with extensive sun damage, history of multiple skin cancers, or precancerous growths. It is often repeated every 2 to 3 years to further decrease the risk of skin cancer.
References
Template:Tumors of bone, cartilage, skin, connective, and soft tissue